No one can hand you an invoice for cloning a person, because no verified human reproductive clone has ever been produced and the procedure is banned or heavily restricted in virtually every country with the capacity to attempt it. Still, the question is not unanswerable. By stitching together the known costs of animal cloning, primate-specific laboratory research, human egg procurement, surrogate pregnancy, cell-line quality control, and the legal liability overhead that would attach to any such project, a rough figure emerges somewhere between several hundred thousand and well over a million dollars per attempt, with no guarantee of success. The reasons for that staggering price tag are worth understanding on their own terms.
What Animal Cloning Tells Us About the Price Floor
The most accessible price point comes from commercial pet cloning. Companies currently charge roughly $50,000 to clone a dog and about $35,000 for a cat. Those figures cover egg retrieval from donor animals, the nuclear transfer procedure, embryo culture, surrogate pregnancies, veterinary care, and some margin of profit. But pets are comparatively easy targets. Dogs and cats have decades of optimized reproductive protocols behind them, and even then the success rate per transferred embryo is low enough that companies typically need multiple surrogates per order.
Livestock cloning offers another data point. The laboratory cost of producing a single cloned cattle embryo ready for transfer has been estimated at around $15 per blastocyst when done at scale, a figure that sounds almost trivially low until you factor in the pregnancy and calving rates, which remain well below the roughly 50% ongoing pregnancy rate that would make large-scale commercial cloning viable.1Reproduction Fertility and Development. Large-scale applications of cloning technologies for agriculture: an industry perspective The economics of cattle cloning underscore a theme that applies even more forcefully to humans: the per-embryo cost is only a fraction of the real expense. The real money goes to surrogates, repeated attempts, veterinary or medical care, and the management of failures along the way.2PubMed. Agro-economic impact of cattle cloning
Why Primate Cloning Is So Much Harder
Cloning gets dramatically more difficult as you move from livestock to primates. The first cloned monkeys from an adult cell were not born until 2018, more than two decades after Dolly the sheep. In that landmark experiment, researchers used 127 high-quality eggs to produce 109 cloned embryos, transferred 79 of them into 21 surrogate mothers, and got exactly two live births. A parallel batch using a slightly different protocol consumed 290 eggs, produced 192 embryos, required 42 surrogates, and again yielded just two live monkeys.3Cell. Cloning of Macaque Monkeys by Somatic Cell Nuclear Transfer That is a success rate of roughly 1-2% per embryo transferred, and it took hundreds of eggs and dozens of surrogates to get there.
Translate those numbers to a human attempt. Human eggs are far more expensive and ethically fraught to obtain than monkey eggs. Human surrogacy is regulated, costly, and legally complex. If you needed hundreds of eggs and dozens of surrogates to have a reasonable shot at one live birth, the costs multiply fast. And the primate data may actually overstate how easy a human version would be, since the macaque protocol relied on donor cells from fetal tissue, which tends to reprogram more readily than adult cells.
The Human Embryo Efficiency Gap
Researchers have attempted somatic cell nuclear transfer with human cells in laboratory settings, stopping well short of implantation. The results reveal just how steep the biological hurdles remain. In one study, only about 11.5% of cleaved human SCNT embryos made it to the blastocyst stage, the point at which an embryo could theoretically be transferred to a uterus.4Cell. Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer A separate experiment using adult donor cells reported blastocyst rates of about 23%, which sounds better but still means that more than three out of four embryos fail before they even reach the stage where implantation could be attempted.5Stem Cells. Development of Human Cloned Blastocysts Following Somatic Cell Nuclear Transfer with Adult Fibroblasts
Keep in mind that making a blastocyst is only the first checkpoint. In animal cloning, plenty of blastocysts that look normal under a microscope still fail to implant, or miscarry, or produce offspring with serious health problems. The incidence of abnormal offspring from cloning remains a major limiting factor across species.6PubMed. Incidence of abnormal offspring from cloning and other assisted reproductive technologies Each failed pregnancy means another round of egg retrieval, embryo creation, and surrogate preparation, and each round carries its own price tag.
Breaking Down the Component Costs
If you were somehow assembling the budget for a human cloning attempt today, you would need to account for at least six major expense categories, each of which is substantial on its own.
- Egg procurement: Human eggs would need to come from donors undergoing hormonal stimulation and surgical retrieval. In the United States, a single egg-retrieval cycle for fertility treatment typically costs $10,000-$15,000 in medical fees alone, plus compensation to the donor. Given that the macaque experiments required well over a hundred eggs per live birth, you might need ten or more retrieval cycles. That is easily $100,000-$200,000 just for the raw biological material.
- Laboratory work: Nuclear transfer requires specialized equipment and highly trained embryologists. The piezo-driven microinjection method, considered the gold standard for minimizing cell damage during the transfer, takes about two minutes per oocyte and damages roughly 10% of them, making it far gentler than older approaches that damaged 37-40% of eggs.7PubMed Central. Technical aspects of the piezo, laser-assisted, and conventional methods for nuclear transfer of mouse oocytes and their efficiency and efficacy The equipment itself is expensive, and the embryologists who can operate it are scarce. A single IVF lab technician in the U.S. handles an average of about 108 fresh egg-retrieval cases per year, working under considerable stress.8Fertility and Sterility. Status of reproductive laboratory professionals in the U.S.: a 20-year update Cloning demands even more specialized skills and more time per case.
- Surrogate pregnancies: Each embryo transfer attempt requires a surrogate, and with success rates in the single digits based on primate data, you would need multiple surrogates. In the U.S., surrogacy arrangements including legal fees, medical costs, and compensation typically run $100,000-$200,000 per pregnancy carried to term. If you need dozens of surrogates to achieve one live birth, as the macaque data suggests, the surrogate budget alone could reach into the millions.
- Cell-line quality control: Before you even begin the cloning procedure, the donor cells must be banked, tested, and verified. Recent cost estimates for clinical-grade cell-line work give a sense of the overhead: karyotyping runs about $450 per cell line, proving that the reprogramming vector has been cleared costs around $1,000 per clone, oncogene screening is roughly $1,600, and identity verification via short tandem repeat analysis adds another $220.9Nature. Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies Those are per-clone costs for research-grade work; clinical-grade verification for a procedure intended to produce a living child would be even more demanding.
- Medical monitoring: A cloned pregnancy would require intensive monitoring for the abnormalities commonly seen in animal clones: oversized fetuses, placental dysfunction, organ defects, and immune problems. That means frequent ultrasounds, specialized blood work, and a delivery team prepared for complications. High-risk obstetric care in the U.S. already runs tens of thousands of dollars; a cloned pregnancy would push that figure higher.
- Legal and liability costs: Any team attempting human cloning would face enormous legal exposure. In conventional assisted reproduction, malpractice claims already carry hefty price tags. One analysis of ART malpractice claims from a single insurance carrier found that total awards over a decade reached about $15 million, with an average payout of roughly $717,000 per claim.10PubMed Central. Outcomes of medical malpractice claims in assisted reproductive technology over a 10-year period from a single carrier Cloning, with its far higher complication rates and uncharted legal territory, would presumably generate even larger claims and insurance premiums.
A Rough Estimate
Add those categories together and the picture comes into focus. Even in an optimistic scenario where only a handful of egg-retrieval cycles and a few surrogates are needed, you are looking at a floor of several hundred thousand dollars. In a more realistic scenario that accounts for the low efficiency rates seen in primates, the total could easily exceed a million dollars per live birth, and possibly several million if the first attempts fail and the process must be repeated. That figure does not include the cost of building or renting the specialized laboratory, hiring the team, or navigating whatever legal framework might theoretically allow the work.
For context, a standard IVF cycle in the United States costs roughly $15,000-$25,000 including medications. Cloning a human would be at least an order of magnitude more expensive than IVF, primarily because the biological efficiency is so much worse and the medical risks are so much higher. The $50,000 price tag for pet dog cloning, already eye-popping for most people, would represent only a small fraction of the cost for a human equivalent.
Could Epigenetic Tricks Bring Costs Down?
One of the main reasons cloning fails so often is that the donor cell’s DNA carries chemical marks, known as epigenetic modifications, that tell the cell “you are a skin cell” or “you are a blood cell.” The egg is supposed to erase those marks and reset the DNA to an embryonic state, but the reprogramming is often incomplete. That is why so many cloned embryos stall out during early development.
Researchers have found that treating cloned embryos with drugs that loosen these chemical marks can substantially improve success rates. In mice, treatment with a compound called trichostatin A after nuclear transfer improved the rate of development to the blastocyst stage by two to five times depending on the donor cell type, and boosted the overall cloning success rate by more than five-fold when using certain cell types.11PubMed. Significant improvement of mouse cloning technique by treatment with trichostatin A after somatic nuclear transfer Follow-up work showed that this drug specifically corrected the expression of genes encoding transcription factors, proteins that act as master switches for other genes during early development.12Scientific Reports. Trichostatin A specifically improves the aberrant expression of transcription factor genes in embryos produced by somatic cell nuclear transfer
Similar epigenetic aids were used in the successful macaque cloning experiments. If these treatments continue to improve, the number of eggs and surrogates needed per live birth could drop, which would meaningfully cut costs. But “meaningfully” here means going from needing, say, 200 eggs to needing 50. You are still looking at a vastly more expensive and failure-prone process than natural reproduction or even standard IVF. The efficiency gains from epigenetic treatment are real, but they are nowhere close to making human cloning routine or affordable.
The Legal Barrier Is Also a Cost Barrier
Even if the biology and the budget were sorted out, the legal landscape makes human reproductive cloning effectively impossible in most of the world. Over 70 countries have laws or regulations that prohibit it. In the United States, there is no federal law explicitly banning human cloning, but the FDA has asserted regulatory authority over the procedure, and many states have their own prohibitions. The European Union bans reproductive cloning under its Charter of Fundamental Rights. China, Japan, Australia, Canada, and most other scientifically advanced nations have similar prohibitions.
These bans have a direct impact on cost. Any attempt would need to occur in a jurisdiction without clear legal prohibitions, which limits the pool of available laboratories, egg donors, surrogates, and medical professionals. Operating outside established regulatory frameworks also means no insurance coverage, no institutional oversight to catch mistakes early, and no clear legal recourse if something goes wrong. The malpractice liability alone would be extraordinary. In legitimate assisted reproduction, the two largest individual malpractice awards in one insurer’s decade-long records were $4.5 million and $3 million, both for diagnostic errors.10PubMed Central. Outcomes of medical malpractice claims in assisted reproductive technology over a 10-year period from a single carrier A cloned child born with serious health defects, a near-certainty given current efficiency rates, could generate liability claims that dwarf those figures.
What About “Therapeutic” Cloning?
Much of the legitimate human SCNT research that has been done falls under the category of therapeutic cloning: creating cloned embryos in order to derive stem cells, not to produce a child. This work is legal in several countries, including the United Kingdom, and is the source of the blastocyst-rate data cited earlier. Therapeutic cloning is considerably less expensive than reproductive cloning would be, because it stops at the blastocyst stage and never involves a surrogate pregnancy, prenatal care, or delivery.
But even therapeutic cloning is not cheap. The cell-line banking costs described earlier apply here, as do the egg-procurement costs. And the low blastocyst rates mean many eggs are needed per successful cell line. Some researchers have turned to induced pluripotent stem cells, a competing technology that reprograms adult cells back to an embryonic-like state using genetic factors rather than egg-based nuclear transfer. That approach avoids the need for human eggs entirely and has become far more practical for most regenerative medicine applications, which has reduced the financial incentive to keep perfecting human SCNT.
The Health Risks That No Budget Can Fully Cover
Cost projections for human cloning inevitably run into a category of expense that is hard to quantify: the medical consequences for the clone. In animals, cloned offspring frequently suffer from a condition sometimes called “large offspring syndrome,” involving oversized fetuses, breathing difficulties at birth, heart and kidney defects, and immune dysfunction. Many cloned animals that survive birth go on to have shortened lifespans or chronic health problems. The abnormality rate in animal cloning remains high enough that it is considered the primary barrier to broader application of the technology.6PubMed. Incidence of abnormal offspring from cloning and other assisted reproductive technologies
For a human clone, these risks would translate into neonatal intensive care, potential surgeries, long-term medical monitoring, and an unknown trajectory of health outcomes that no physician has ever managed before. The first cloned human would be, in every medical sense, an experiment of one. Budgeting for their healthcare would require accounting for scenarios that have no precedent in human medicine, which makes any cost estimate inherently speculative at the tail end.
There is also the psychological dimension. A cloned person would be genetically identical to their donor but would develop in a different uterine environment, at a different time, with different life experiences. They would not be a copy of the donor in any meaningful behavioral or personality sense. But they would live in a world that might treat them as one, raising questions about identity, autonomy, and social stigma that no amount of money can preemptively resolve.
Why Pet Cloning Prices Are a Poor Guide
People sometimes look at the $50,000 dog-cloning price tag and assume human cloning would be in the same ballpark, just with a markup. The comparison badly underestimates the gap. Pet cloning companies use dog eggs collected from ovaries removed during routine spay surgeries, which are abundant and essentially free. Human eggs require hormonal stimulation, medical screening, and surgical retrieval from compensated donors. Pet cloning surrogates are colony dogs housed and maintained by the company at relatively modest cost. Human surrogates require legal contracts, insurance, prenatal care, and compensation that reflects the physical burden and risk of pregnancy.
The regulatory environment is also completely different. Pet cloning companies operate in a largely unregulated space. There is no FDA approval required, no equivalent of an institutional review board overseeing animal welfare to the degree that human subjects research demands, and no liability framework comparable to medical malpractice law. A pet cloning failure is a sad outcome and a business loss. A human cloning failure could be a criminal act, a multi-million-dollar lawsuit, and a medical emergency for both the surrogate and the child.
The one useful thing pet cloning does tell us is that even under the most favorable economic conditions, with cheap eggs, cheap surrogates, minimal regulation, and decades of optimized protocols, commercial cloning still costs tens of thousands of dollars per animal. Scale every one of those inputs up by an order of magnitude or more, add the unique complications of primate biology and human medicine, and you begin to see why serious estimates for human cloning start in the high six figures and climb from there.